MedTrace Logo

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

NCT05812430 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-09-13

No results posted yet for this study

Summary

To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer

Conditions

  • Advanced Biliary Tract Cancer

Interventions

DRUG

anlotinib+TQB2450+nab-paclitaxel+cisplatin

Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity. TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity. nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles.

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2023-10-10
Completion
2024-10-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05812430 on ClinicalTrials.gov